Beyondspring Inc

자세한 내용은 Beyondspring Inc 회사

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

회사 정보

종목 코드 BYSI

회사 이름Beyondspring Inc

상장일Mar 09, 2017

CEODr. Lan Huang, Ph.D.

직원 수40

유형Ordinary Share

회계 연도 종료Mar 09

주소100 Campus Drive, West Side, 4Th Floor

도시FLORHAM PARK

증권 거래소NASDAQ Capital Market Consolidated

국가United States of America

우편 번호07932

전화16465284184

웹사이트https://www.beyondspringpharma.com/en/

종목 코드 BYSI

상장일Mar 09, 2017

CEODr. Lan Huang, Ph.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Lan Huang, Ph.D.

Chairperson of the Board, Chief Executive Officer, Co-Founder

4.26M

--

Mr. Patrick (Pat) Fabbio

Independent Director

53.86K

+119.03%

Dr. Jiangwen (Jen) Majeti, Ph.D.

Independent Director

50.91K

--

Dr. June Lu, Ph.D.

Chief Scientific Officer

--

Mr. Sihai Xu

Director

--

Mr. Brendan P. Delaney

Independent Director

--

Mr. Matthew Kirkby

Independent Director

--

-100.00%

이름

이름/직위

직위

주식 보유

변동

Dr. Lan Huang, Ph.D.

Chairperson of the Board, Chief Executive Officer, Co-Founder

4.26M

--

Mr. Patrick (Pat) Fabbio

Independent Director

53.86K

+119.03%

Dr. Jiangwen (Jen) Majeti, Ph.D.

Independent Director

50.91K

--

Dr. June Lu, Ph.D.

Chief Scientific Officer

--

Mr. Sihai Xu

Director

--

Mr. Brendan P. Delaney

Independent Director

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, Jul 19

주주

주주 유형

주주

비율

Decheng Capital LLC

12.11%

Huang (Lan)

10.58%

Jia (Linqing)

4.43%

The Vanguard Group, Inc.

1.30%

BlackRock Institutional Trust Company, N.A.

0.29%

Other

71.30%

주주

비율

Decheng Capital LLC

12.11%

Huang (Lan)

10.58%

Jia (Linqing)

4.43%

The Vanguard Group, Inc.

1.30%

BlackRock Institutional Trust Company, N.A.

0.29%

Other

71.30%

주주 유형

주주

비율

Individual Investor

15.26%

Venture Capital

12.11%

Investment Advisor

1.69%

Investment Advisor/Hedge Fund

0.35%

Hedge Fund

0.13%

Bank and Trust

0.09%

Research Firm

0.03%

Other

70.33%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

62

11.96M

29.67%

-626.00K

2025Q1

65

11.44M

28.38%

-1.18M

2024Q4

71

11.41M

28.30%

-5.42M

2024Q3

73

15.85M

39.34%

-1.46M

2024Q2

85

16.08M

39.89%

-939.10K

2024Q1

128

16.18M

41.46%

-1.22M

2023Q4

143

15.76M

40.39%

-1.74M

2023Q3

172

17.23M

44.26%

-3.36M

2023Q2

182

17.28M

44.39%

-4.16M

2023Q1

198

17.53M

45.04%

-4.14M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Decheng Capital LLC

4.88M

12.11%

-75.49K

-1.52%

Mar 31, 2025

Huang (Lan)

4.26M

10.58%

--

Feb 28, 2025

Jia (Linqing)

1.78M

4.43%

+4.00

+0.00%

Feb 28, 2025

BlackRock Institutional Trust Company, N.A.

115.97K

0.29%

-1.09K

-0.93%

Mar 31, 2025

BlackRock Financial Management, Inc.

90.54K

0.22%

--

Mar 31, 2025

Fabbio (Patrick)

53.86K

0.13%

+29.27K

+119.03%

Feb 28, 2025

Majeti (Jiangwen)

50.91K

0.13%

--

Feb 28, 2025

UBS Switzerland AG

34.93K

0.09%

-17.48K

-33.35%

Mar 31, 2025

Tanaka Capital Management, Inc.

26.30K

0.07%

-3.18K

-10.78%

Mar 31, 2025

2.190USD

Beyondspring Inc

2.190

개요

회사

금융